Authorized purpose: SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Clinical role
MRI image enhancement or post-processing support before routine professional interpretation.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Supported image size, anatomy, sequence, input quality, and processing options are release-specific; processed images require review against the source study. SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Supported DICOM MRI images and release-specific processing parameters.
Who uses it?Intended users: Qualified MRI technologists and interpreting physicians.
What does the software produce?Output: Processed or enhanced MR image objects for review and downstream archival.
What is its most important limitation?Key limitation: Supported image size, anatomy, sequence, input quality, and processing options are release-specific; processed images require review against the source study. SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Clinical takeaway. Clinical role: SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing plus a retrospective clinical-data performance study divided into two tests. Noise reduction acceptance criteria: ROI signal-to-noise ratio improved on average by greater than or equal to 5% versus original images, and small-structure visibility before and after enhancement on average less than or equal to 0.5 Likert scale points; passed. Sharpness enhancement acceptance criteria: structure thickness and boundary sharpness improved in at least 90% of test datasets; passed. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
Supported image size, anatomy, sequence, input quality, and processing options are release-specific; processed images require review against the source study. SubtleMR is MRI image-processing software for reducing noise in supported head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI or increasing sharpness for head MRI within the labeled workflow.
The exact FDA document reports software verification and validation testing plus a retrospective clinical-data performance study divided into two tests. Noise reduction acceptance criteria: ROI signal-to-noise ratio improved on average by greater than or equal to 5% versus original images, and small-structure visibility before and after enhancement on average less than or equal to 0.5 Likert scale points; passed. Sharpness enhancement acceptance criteria: structure thickness and boundary sharpness improved in at least 90% of test datasets; passed. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Subtle Medical conducted the following performance testing: • Software verification and validation testing • Study that utilized retrospective clinical data to demonstrate the software enhanced image quality in MR images via a reduction of noise or sharpness enhancement." … "The main performance study, utilizing retrospective clinical data, was divided into two tests.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation testing plus a retrospective clinical-data performance study divided into two tests. Noise reduction acceptance criteria: ROI signal-to-noise ratio improved on average by greater than or equal to 5% versus original images, and small-structure visibility before and after enhancement on average less than or equal to 0.5 Likert scale points; passed. Sharpness enhancement acceptance criteria: structure thickness and boundary sharpness improved in at least 90% of test datasets; passed. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Subtle Medical conducted the following performance testing: • Software verification and validation testing • Study that utilized retrospective clinical data to demonstrate the software enhanced image quality in MR images via a reduction of noise or sharpness enhancement." … "The main performance study, utilizing retrospective clinical data, was divided into two tests.". Read from the exact FDA decision document on 2026-11-14.
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K203182
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K203182.
PopulationThe labeled population and test materials for exact submission K203182; a general clinical study population is not established here.
Scopeexact submission
Tested versionSubtleMR (K203182)
IndependenceSponsor or vendor study
K203182
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
2 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM MRI images and release-specific processing parameters.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes SubtleMR processing DICOM-compliant image data from the file system and storing enhanced images on the file system, with receipt of original DICOM files and delivery of enhanced DICOM files depending on other software systems. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "DICOM The software processes DICOM Same Standard compliant image data" … "The software operates on DICOM Same files on the file system, enhances the images, and stores the enhanced images on the file system.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Processed or enhanced MR image objects for review and downstream archival.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Processed or enhanced MR image objects for review and downstream archival.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes SubtleMR processing DICOM-compliant image data from the file system and storing enhanced images on the file system, with receipt of original DICOM files and delivery of enhanced DICOM files depending on other software systems. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DICOM The software processes DICOM Same Standard compliant image data" … "The software operates on DICOM Same files on the file system, enhances the images, and stores the enhanced images on the file system.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Current vendor material is product-family context for K203182 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.
SubtleMR V2.0.0 · K203182. Name for this exact FDA record, not an alias for every commercial configuration. Name source
SubtleMR 2.3.x · K223623. Name for this exact FDA record, not an alias for every commercial configuration. Name source
SubtleMR image enhancement
MRI noise reduction and head-image sharpness enhancement. Applies to K203182, K223623. This describes the mapped function only; feature parity and a shared license are not established.
K223623 · 2023-05-11. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: SIGNA Bolt is a whole-body MRI system for high-resolution diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.
Authorized purpose: SIGNA Sprint Select is a whole-body MRI system for diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.
Authorized purpose: SIGNA Sprint is a 1.5T whole-body MRI system for diagnostic imaging of the labeled head, neck, TMJ, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal regions.
Authorized purpose: SIGNA Prime Elite is a whole-body MR system that produces cross-sectional, spectroscopic, parametric, and dynamic images of the labeled body regions for trained physician interpretation, with contrast use depending on the region and protocol.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.